Prilenia Therapeutics plans MAA submission to CHMP for pridopidine
Prilenia Therapeutics has announced its intention to submit a marketing authorization application (MAA) for pridopidine, aimed at treating Huntington's disease (HD), to the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP).